PIK3CA and breast carcinoma: Another qPCR-based test, therascreen PIK3CA RGQ PCR Kit from QIAGEN GmbH, was FDA approved for PIK3CA mutation detection in liquid biopsy for postmenopausal, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2-)-negative advanced breast cancer patients before administration of alpelisib in combination with fulvestrant [48].